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Purpose: To explore the in vivo anti-angiogenesis effects resulting from lentivirus-mediated RNAi of vascular endothelial
growth factor (VEGF) in monkeys with iris neovascularization (INV).
Methods: Five specific recombinant lentiviral vectors for RNA interference, targeting Macaca mulatta VEGFA, were
designed and the one with best knock down efficacy (LV-GFP-VEGFi1) in H1299 cells and RF/6A cells was selected by
real-time PCR for in vivo use. A laser-induced retinal vein occlusion model was established in one eye of seven cynomolgus
monkeys. In monkeys number1, 3, and 5 (Group 1), the virus (1×108 particles) was intravitreally injected into the preretinal
space of the animal's eye immediately after laser coagulation; and in monkeys number 2, 4, and 6 (Group 2), the virus
(1×108 particles) was injected at 10 days after laser coagulation. In monkey number 7, a blank control injection was
performed. In monkeys number 1 and 2, virus without RNAi sequence was used; in monkeys number 3 and 4, virus with
nonspecific RNAi sequence was used; and in monkeys 5 and 6, LV-GFP-VEGFi1 was used.
Results: In monkey number 5, at 23 days after laser treatment, no obvious INV was observed, while fluorescein
angiography of the iris revealed high fluorescence at the margin of pupil and point posterior synechiae. At 50 days after
laser treatment, only a slight ectropion uvea was found. However, in the other eyes, obvious INV or hyphema was observed.
The densities of new iridic vessels all significantly varied: between monkey number 5 and number 3 (36.01±4.49/mm2
versus  48.68±9.30/mm2,  p=0.025),  between  monkey  number  3  and  monkey  number  7  (48.68±9.30/mm2  versus
74.38±9.23/mm2, p=0.002), and between monkey number 5 and number 7 (36.01±4.49/mm2 versus 74.38±9.23/mm2,
p<0.001).
Conclusions: Lentivirus-mediated RNAi of VEGF may be a new strategy to treat iris neovascularization, while further
studies are needed to investigate the long-term effect.
Iris  neovascularization  (INV)  and  subsequent
neovascular glaucoma (NVG) are serious complications for
patients with retinal ischemia, which may attribute to central
retinal vein occlusion, proliferative diabetic retinopathy or
other ischemic retinal disorders [1].
Vascular  endothelial  growth  factor  (VEGF),  an
endothelial-cell-specific angiogenic factor whose production
is increased by hypoxia, is considered to be the best studied
key  molecule  in  ocular  neovascularization  [2,3].  Elevated
levels of VEGF have been identified in the aqueous humor of
patients with rubeosis and NVG [4].
Panretinal photocoagulation (PRP) has became the most
commonly-used therapy to obliterate newly formed vessels in
varied ischemic retinal disease [1,5,6]. However, in patients
with  severe  media  opacity  such  as  cataracts  or  vitreous
hemorrhage, PRP can not be performed. In addition, common
side effects of PRP include worsened visual field, decreased
night vision, diminished color vision, and decreased contrast
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sensitivity.  Therefore,  it  is  necessary  seek  alternative  or
adjunctive therapeutic strategies in the treatment of ocular
angiogenic diseases.
Recently, intraocular injections of VEGF antibody have
shown  encouraging  outcomes  for  management  of  INV:
intracameral or intravitreal injections of bevacizumab, a full-
length antibody of VEGF, can lead to complete or partial
reduction  of  INV  in  92.8%—100%  of  subjects  [7-9].
Nevertheless,  due  to  the  short  half-life  of  bevacizumab,
recurrence of INV can be observed as early as 4 weeks after
injection [7], thus repeated multiple injections are necessary.
Therefore, one may postulate that the next improvement
in treatment of INV would extend anti-VEGF therapy to allow
stable and long-term suppression of the overactive VEGF
pathway.  RNA  interference  (RNAi)  has  emerged  as  a
powerful tool to induce loss-of-function phenotypes by post-
transcriptional silencing of gene expression [10]. In this study,
in contrast to the relatively short-lived siRNA used in previous
studies [11,12], we used a lentiviral vector expressing a small
hairpin RNA (shRNA) in the monkey INV model system,
which potentially allows longer term suppression, relative to
ectopically administered RNA, siRNA, and oligonucleotides,
of  overexpressed  VEGF  due  to  the  innate  longevity  of
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1743expression from integrated or episomally stable DNA vectors.
Lentivirus vectors have been shown to express transgenes
steadily and potently for months or years [13,14].
METHODS
Lentivirus vectors for VEGF small hairpin RNA: shRNA of
Macaca  mulatta  VEGFA  lentivirus  gene  transfer  vector
encoding  green  fluorescent  protein  (GFP)  sequence  was
constructed by Genechem Co., Ltd, Shanghai, China (Figure
1). Five targeting sequences of the shRNA were designed as
follows:  5′-  AAT  GCA  GAC  CAA  AGA  AAG  ATA-3′
(VEGFi1),  5′-AGG  GCA  GAA  TCA  TCA  CGA  AGT-3′
(VEGFi2),  5′-CGA  ACG  TAC  TTG  CAG  ATG  TGA-3′
(VEGFi3),  5′-GAC  GTG  TAA  ATG  TTC  CTG  CAA-3′
(VEGFi4), and 5′-ATG CGG ATC AAA CCT CAC CAA-3′
(VEGFi5;  GenBank  XM_001089925).  The  lentivirus-GFP
(LV-GFP) which included the GFP gene and did not include
the VEGFA interference sequence served as negative control,
and the target sequence, VEGFiCON (5′-TTC TCC GAA
CGT GTC ACG T-3′), was designed with a randomly chosen
nonsense  sequence  to  serve  as  an  additional  control.  The
shRNA was confirmed by sequencing.
The recombinant lentivirus coding shRNA and targeting
VEGFA  (LV-GFP-VEGFi1,  LV-GFP-VEGFi2,  LV-GFP-
VEGFi3, LV-GFP-VEGFi4, and LV-GFP-VEGFi5) and the
negative control (LV-GFP-VEGFiCON and LV-GFP) were
prepared and titered to 107 TU/ml (where TU is transfection
unit).
Cell culture and infection: Established H1299 cells and a
rhesus monkey choroid-retina endothelial cell line (RF/6A)
were  obtained  from  the  ATCC  (American  Type  Culture
Collection, Rockville, MD). The H1299 cells and RF/6A cells
were cultured in Dulbecco’s Modified Eagle Medium/F12
(Gibco, Grand Island, NY) with 10% fetal bovine serum. Cells
were incubated at a constant 37 °C in a humidified incubator
containing 5% CO2 −95% air. When the cells were about 50%
confluent in complete DMEM medium, they were infected
with the lentivirus constructs at different MOI (Multiplicity
of Infection, or infectious unit ratio).
Quantitative Real-Time PCR in vitro studies: To detect the
efficiency of interference for VEGF, 1×106 H1299 cells were
transfected  by  LV-GFP-VEGFi(1–5),  respectively,  with
2×107 (MOI=20, High MOI group) or 1×106 (MOI=1, Low
MOI group) particles. The LV-GFP-VEGFiCON and LV-
GFP served as negative controls. The cells were harvested
Figure 1. Construction of a lentivirus-
mediated  shRNA  of  Macaca  mulatta
VEGFA.
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1744after 7 days for Quantitative Real-Time PCR of VEGF. The
sequences  of  the  VEGF  primers  were  as  follows:  VEGF
forward primer 5′-CAG ATG TGA CAA GCC GAG G-3′,
VEGF reverse primer 5′-GCT GTC TAA TGC CCT GGA
G-3′. Based on the result, the two LV-GFP-VEGFi with the
highest knock-down efficiency were selected. In the second
step, the two LV-GFP-VEGFi were used to transfect RF/6A
cells in a similar way. Finally, the one sequence with the
highest knock-down efficiency was selected for in vivo study.
Experimental  iris  neovascularization:  Seven  cynomolgus
monkeys (Macaca fasicularis) were used in this experiment
in accordance with the Association for Research in Vision and
Ophthalmology's  Resolution  on  the  Use  of  Animals  in
Research.  Only  the  left  eye  was  used.  Using  methods
previously reported an induced ischemic branch retinal vein
occlusion  was  performed  to  establish  the  iris
neovascularization  model  [15].  The  monkeys  were
anesthetized with an intramuscular injection of a mixture of
20  mg/kg  bodyweight  ketamine  hydrochloride  (Ketalar,
Parke-Davis,  Morris  Plains,  NJ),  1  mg/kg  bodyweight  of
diazepam (Elkins-Sinn, Cherry Hill, NJ) and 0.125 mg/kg
bodyweight of atropine sulfate (Dexter Corporation, Chagrin
Falls, OH) for each examination and procedure. The eyes were
gently protruded using an eye speculum and the pupils were
dilated with 1% tropicamide [16]. Solid state laser light (532
nm, Novus spectra; Lumenis® Ltd, Santa Clara, CA) was used
to occlude all branched retinal veins of the monkey eyes. The
other laser parameters were: spot size 300 µm, power 300—
360 mW, and exposure duration 200 ms.
Monkey group information: After retinal vein occlusion, the
monkeys were divided into two groups. In group 1 (monkeys
number 1, 3, and 5), the virus (1×108 particles per eye) was
intravitreally injected into the preretinal space of the animal’s
eye right after laser coagulation; and in group 2 (monkeys
number 2, 4, and 6), the virus (1×108 particles per eye) was
injected  at  10  days  after  laser  coagulation  (Table  1).  In
monkey number 7, the injection was performed but without
actually injecting anything. The intravitreal injections were
performed with a 26-gauge needle and the incision was made
2 mm behind the limbus. The needle was inserted tangentially
toward the posterior pole of the eye, and about 100 µl of viral
suspension was injected to the preretinal space. The injections
were performed under a surgical microscope and the fundus
could be observed during injection.
Evaluation  of  iris  neovascularization  model:  Iris
neovascularization was evaluated by slit-lamp examination,
iris  photography,  and  fluorescein  angiography  of  the  iris
(IFA).  Angiography  was  performed  with  10%  sodium
fluorescein  (0.1  ml/kg  bodyweight)  via  saphenous  vein
injection [16]. Fifty days after laser coagulation, animals were
sacrificed  by  overdose  of  anesthesetic  and  the  eyes  were
carefully enucleated and placed in 4% formalin(in 0.1 M PBS)
overnight. The eyes were then grossly dissected and the nasal
part of the globes was removed.
Histopathological analysis of iris neovascularization: The
globe was processed and embedded in paraffin. Serial sections
were  performed  and  stained  with  hematoxylin  and  eosin
[17]. The section was immunohistochemically stained with
antibody  to  factor  VIII-related  antigen/von  Willebrand's
factor (factor VIII) according to the methods of Noel Weidner
[18]. Neogenic vessels are marked by factor VIII, but normal
iridic vessels are not stained. Sections (5) were randomly
selected  from  each  group  (eye)  for  factor  VIII  staining.
Meanwhile, the calculation for positive INV on each section
was conducted under the microscope; the iris section area was
calculated with software Scion Image. The INV density on
each iris section could be derived based on the two above
parameters per mm2.
Statistical analysis: Statistical analysis was performed using
a commercially available statistical software package (SPSS
for  Windows,  version  16.0;  SPSS,  Chicago,  IL).  The
independent t-test was used to compare the density of iridic
new  vessels  between  groups.  The  data  were  distributed
normally and are presented as the mean±SD. All p-values
were two-tailed and were considered statistically significant
when the values were less than 0.05.
RESULTS
Comparison of interference efficacy between different designs
of  lentivirus-GFP-shRNA  and  control:  All  five  LV-GFP-
VEGFi were tested in vitro. First, the Real-Time RT–PCR in
H1299 cells demonstrated that LV-GFP-VEGFi1 and LV-
TABLE 1. THE EXPERIMENTAL TREATMENT OF THE IRIS NEOVASCULARIZATION MODEL ESTABLISHED IN 7 MONKEYS.
Monkey Lentivirus type Injection time after laser coagulation (days) Group
1 LV-GFP right after laser 1
2 LV-GFP 10 2
3 LV-GFP-VEGFiCON right after laser 1
4 LV-GFP-VEGFiCON 10 2
5 LV-GFP-VEGFi1 right after laser 1
6 LV-GFP-VEGFi1 10 2
7 sham control fake injection -
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1745GFP-VEGFi5 are the most efficient shRNA. According to the
ratio of shRNA to control, the VEGF levels were all decreased
by more than 70% either in the high MOI or the low MOI
group (Figure 2A,B and Table 2). Second, we tested LV-GFP-
VEGFi1 and LV-GFP-VEGFi5 in the RF/6A cells, and the
results  obviously  indicated  that  LV-GFP-VEGFi1  could
inhibit expression of VEGF, and was superior to LV-GFP-
VEGFi5 (Figure 2C,D and Table 2): in the high-MOI group
(Figure  2D),  the  LV-GFP-VEGFi1  and  LV-GFP-VEGFi5
knock-down  efficiencies  were  64.2%  and  60.8%,
respectively; in the low-MOI group (Figure C), the knock-
down efficiencies were 69.1% and 33.7%, respectively. Third,
we packaged the screened shRNA and selected LV-GFP-
VEGFi1  to  co-transfect  293T  cells  with  pHelper  1.0  and
Helper  2.0;  the  high  titer  Lentivirus  were  harvested  and
purified for in vivo experiments [19].
Establishment  of  the  INV  model:  Laser  irradiation  was
successfully performed to occlude all major branched retinal
veins of the monkeys’ eyes (Figure 3A). In monkey number
7, which served as sham control, obvious venous dilation and
corresponding retinal hemorrhage can be observed from 2
days after laser coagulation (Figure 3B); at 7 days after laser
coagulation, mild iris neovascularization can be observed at
the margin of the pupil with slight leakage of fluorescein
(Figure 3C,D); and at 14 days after laser coagulation, severe
and tortuous iris neovascularization can be observed at the
whole iris with strong leakage of fluorescein (Figure 3E,F),
which lasted to 1 month after laser coagulation (Figure 3G,H).
Effect  of  VEGF-RNAi:  Severe  bacterial  endophthalmitis
occurred in monkeys number 1 and number 2 at 3 days after
intravitreal  injection  of  LV-GFP.  Therefore,  the  data  of
monkey number 1 and number 2 were discarded.
In monkey number 3, at 23 days after laser coagulation,
moderate iris neovascularization was observed throughout the
whole iris with obvious leakage of fluorescein (Figure 4A,B).
At 50 days, un-regressed new blood vessels could still be
observed throughout the whole iris with obvious leakage of
fluorescein at IFA, but the leakage was less severe than that
observed at day 23. Meanwhile, severe ectropion uvea could
be observed (Figure 5A).
In  monkey  number  4,  after  laser  coagulation,  severe
hyphema prevented the observation of the iris (Figure 4C,D).
At 50 days, secondary glaucoma occurred (severe corneal
epithelium edema was present; Figure 5B).
In monkey number 5, at 23 days after laser coagulation,
no obvious iris neovascularization was observed under slit-
Figure 2. Gene silencing by lentiviral
delivery of VEGFA siRNA. In the study
with H1299 cells (A and B), expression
of VEGFA was lower after blocking by
siRNA sequences KD1 and KD5 than
the other three sequences, under both the
low MOI and high MOI. In the study
with RF/6A cells (C and D), expression
of VEGFA was lower after blocking by
siRNA sequence KD1 than KD5, under
both low MOI and high MOI. In the
High  MOI  group,  MOI=20,  which
means that 1×106 cells were transfected
by 2×107 particles of virus. In the Low
MOI group, MOI=1, which means that
1×106 cells were transfected by 1×106
particles of virus (CON: blank control;
NC:  negative  control;  KD1–5:  knock
down  1–5;  MOI:  Multiplicity  of
Infection).
TABLE 2. INTERFERENCE EFFICACY OF LENTIVIRUS-GFP-SHRNA IN CELLS.
    CON NC KD1 KD2 KD3 KD4 KD5
H1 299 MOI=1 1.00±0.06 0.98±0.10 0.27±0.08 0.42±0.17 0.71±0.08 0.67±0.18 0.31±0.09
  MOI=20 1.00±0.13 0.68±0.16 0.14±0.05 0.23±0.11 0.20±0.08 0.32±0.10 0.19±0.04
RF/6A MOI=1 1.00±0.18 0.88±0.22 0.31±0.13 – – – 0.66±0.19
  MOI=20 1.00±0.12 0.66±0.25 0.36±0.11 – – – 0.40±0.03
        The values of this table represent the ratio of VEGF expression level in each group to control.
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1746Figure 3. Color photograph and fluorescein angiography of the iris of monkey number 7 which underwent fake intravitreal injection. Laser
irradiation was performed to occlude all major branched retinal veins of the monkey’s eyes (A). Obvious venous dilation and corresponding
retinal hemorrhage can be observed from 2 days after laser coagulation (B); at 7 days after laser coagulation, mild iris neovascularization can
be observed at the margin of pupil (C) with slight leakage of fluorescein (D); and at 14 days after laser coagulation, severe and tortuous iris
neovascularization can be observed across the whole iris (E) with strong leakage of fluorescein (F) which lasted to 23 days after laser
coagulation (G and H).
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1747Figure 4. Color photograph and fluorescein angiography of irises of monkeys at 23 days after laser coagulation. In monkey number 3, moderate
iris neovascularization (A) can be observed through the whole iris with obvious leakage of fluorescein (B). In monkey number 4, severe
hyphema prevented the observation of iris (C and D). In monkey number 5, no obvious iris neovascularization (E) can be observed, while
IFA revealed high fluorescence at the margin of pupil and point posterior synechiae (F). In monkey number 6, thin iris neovascularization
can be observed through the whole iris together with an irregular and fixed pupil. Ectropion uveae and hemorrhages adhering to the anterior
surface of lens were present (G).
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1748lamp  examination  (Figure  4E),  while  IFA  revealed  high
fluorescence  at  the  margin  of  pupil  and  point  posterior
synechiae (Figure 4F). At 50 days, IFA revealed a less severe
leakage of fluorescein. A slight ectropion uvea was found
(Figure 5C).
In monkey number 6, after laser coagulation, new thin iris
vessels were observed throughout the whole iris together with
an irregular and fixed pupil. Ectropion uveae and hemorrhages
adhering to the anterior surface of lens were present (Figure
4G). At 50 days, the findings were similar that hemorrhage,
new  thin  iris  vessels,  an  irregular  and  fixed  pupil,  and
ectropion uveae were observed (Figure 5D).
For  a  better  illustration  of  in  vivo  experiments,  we
summarized the results in different groups and stages, and
tabulated these data in Table 3.
Histopathological examination of iris: Table 4 showed the
density  of  iris  new  vessels  counted  microscopically.  The
density of iridic new vessels were lowest in monkey number
5 which underwent intravitreal injection of LV-GFP-VEGFi1
immediately  after  laser  coagulation  of  the  retinal  veins
(36.01±4.49/mm2) and highest in monkey number 4 which
received an intravitreal injection of LV-GFP-VEGFiCON at
10 days after laser coagulation of retinal veins (77.12±10.79/
mm2). In monkeys number 3, number 6, and number 7, the
density  of  iridic  new  vessels  were  48.68±9.30/mm2,
68.14±9.87/mm2, and 74.38±9.23/mm2, respectively. Figure
6 A,B showed the new vessels of iris in monkey number 5 and
number 7. A remarkable fibrosis membrane at the anterior
surface of iris in monkey number 7 and number 3 (Figure 6C),
but it was not observed in other monkeys.
The following differences in new iridic vessel density
were significant: between monkey number 5 (group 1) and
monkey  number  3  (group  1;  p=0.025),  between  monkey
number 3 (group 1) and monkey number 7 (blank; p=0.002),
and between monkey number 5 (group 1) and monkey number
7 (blank; p<0.001).
Figure 5. Color photograph iris of monkeys at 50 days after laser coagulation. In monkey number 3, un-regressed new blood vessels still can
be observed throughout the whole iris (A). In monkey number 4, secondary glaucoma occurred (severe corneal epithelium edema was present;
B). In monkey number 5, slight ectropion uvea was found (C). In monkey number 6, new thin iris vessels can be observed through the whole
iris together with an irregular and fixed pupil. Ectropion uveae were apparently observed (D).
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1749There were no significant difference observed between
monkey number 4 (group 2) and monkey number 6 (group 2),
between monkey number 4 (group 2) and monkey number 7
(blank), and between monkey number 6 (group 1) and monkey
number 7 (blank) in density of new iridic vessels (p>0.05).
DISCUSSION
Results showed that iris neovascularization morphologically
regressed  in  the  monkey  which  underwent  intravitreal
injection of lentiviral vector expressing anti-VEGF shRNA
immediately after laser coagulation of branched retinal veins
to  establish  INV  model.  However,  severe  iris
neovascularization or ectropion uvea were observed in the
monkey which underwent intravitreal injection of lentiviral
vector expressing anti-VEGF shRNA at 10 days after laser
coagulation  of  branched  retinal  veins.  Accordingly,  the
density of new iridic vessels was significantly lower in the eye
with immediate intravitreal injection of shRNA-LentiVirus
than the control eye with fake intravitreal injection, and lower
than the monkey eye with intravitreal injection of shRNA-
LentiVirus at 10 days after establishment of INV.
The  present  results  were  consistent  with  a  recently
reported study that used small interference RNA targeting
VEGF to inhibit corneal neovascularization in the rat model
[20]. In this study, corneal neovascularization was induced by
cauterization  with  sodium  hydroxide  in  rat  corneas.  The
VEGF-siRNA-transfected  corneal  epithelium  cells  were
transplanted  to  CNV  lesions.  Immediately  after
transplantation,  the  VEGF-siRNA  combined  with
lipofectamine were directly injected into the anterior chamber
to transfect the rat cornea. The authors found that the levels
of  expression  of  both  VEGF  mRNA  and  protein  in  the
VEGF-siRNA  transfected  corneal  epithelial  cells  and
keratocytes were significantly lower than in controls. The
new-vessels-occupied  surface  areas  of  the  VEGF-siRNA-
transfected-corneal  epithelium  transplantation  group  were
also significantly less than the control group.
A similarly positive outcome was observed by Murata et
al.  [21].  They  found  that  exposure  to  diced  siRNAs
significantly reduced VEGF mRNA expression in ARPE-19
cells  with  minimal  toxicity.  In  suture-induced  corneal
angiogenesis models, diced siRNAs minimized the severity
of angiogenesis.
In  addition,  using  RNA  interference  to  block  the
expression of VEGF was reportedly effective for choroidal
neovascularization  [11],  and  diseases  other  than  ocular
TABLE 3. IMAGING OBSERVATION RESULTS OF ANTERIOR SEGMENT OF MONKEYS.
Group No. Days INV Leakage of
fluorescein
Posterior
synechia of
pupil
Ectropion
uvea
NVG Hyphema
1 3 23 + +++ + – – –
    50 + + + – – –
  5 23 – ++ + – – –
    50 – + – – – –
2 4 23 * +++ * * – +++
    50 ++ ++ ++ +++ ++ –
  6 23 ++ ++ ++ + – +
    50 + + ++ + – –
CON 7 23 +++ +++ – – – –
    50 ++ ++ + ++ + –
        In the table, INV indicates iris neovascularization and NVG indicates neovascular glaucoma. The asterisk indicates that severe
        hyphema prevented the observation of the iris.
TABLE 4. DENSITY OF NEW IRIS VESSELS IN MONKEY EYES (N=1).
Monkey No. 3 No. 4 No. 5 No. 6 No. 7
RNAi injected VEGFiCON VEGFiCON VEGFi1 VEGFi1 sham injection
Group Group 1 Group 2 Group 1 Group 2  
Density of INV 48.68±9.30/mm2 77.12±10.8/mm2 36.01±4.49/mm2 68.14±9.87/mm2 74.38±9.23/mm2
Comparison of density of INV
Between monkeys
No. 3 – – p=0.025 – p=0.002
No. 4 – – – p>0.05 p>0.05
No. 5 p=0.025 – – – p<0.001
No. 6 – p>0.05 – – p>0.05
No. 7 p=0.002 p>0.05 p<0.001 p>0.05 –
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1750angiogenic diseases, such as colorectal cancer [22,23] and
breast carcinoma [24].
Since the efficacy and mode of delivery of siRNA, a
therapeutic tool, vary considerably [25], one should take the
method of delivery into account. Chemically or enzymatically
synthesized siRNA is costly and has been shown to have a
relatively  short  half-life,  with  only  transient  inhibition  of
target  genes  [26].  Repeated  administration  of  siRNA  can
compensate for the reagent's short half-life with the drawback
that  the  risk  of  complications  of  intraocular  injections
increase. It has been reported that lentiviruses can efficiently
transduce cells [27] and lentiviral delivery of siRNA can allow
for efficient and stable gene silencing [28], therefore, we
tested the efficacy of RNAi for VEGF by lentiviral delivery
in our study.
Interestingly,  obvious  regression  of  iris
neovascularization was only observed in the monkeys which
underwent  intraocular  injection  of  lentiviral  delivery  of
shRNA  for  VEGF  immediately  after  laser  coagulation  of
branched  retinal  veins.  Severe  iris  neovascularization  or
ectropion  uvea  were  still  present  in  the  monkey  which
underwent the same injection at 10 days after laser coagulation
of branched retinal veins. One may infer that although virus-
mediated RNAi for VEGF can achieve a long-term and stable
gene silencing, it may be effective only if used at the early
stages of retinal ischemia. The mechanism of action needs
more investigation to reveal why this time difference occurs.
The limitations of this study should be mentioned. First,
the  number  of  monkeys  used  in  this  study  was  small.
Therefore, data for incidence of complications with minor
risks of intraocular use of lentiviral delivery of shRNA for
VEGF were not obtainable, and the present results can only
be regarded as preliminary. Second, the follow-up time was
relatively short. The long-term effect of this kind of strategy
should be investigated in future studies.
Figure 6. Immunohistochemistry of VIII
factor  for  number  counting  of  new
vessels of iris. The density of iridis new
vessels in the monkey number 5 (A) was
36.01±4.49/mm2  and  74.38±9.23/mm2
in monkey number 7 (B). In monkey
number  3,  a  remarkable  fibrosis
membrane at the anterior surface of iris
was observed (arrows, C). The original
magnification was: 50× for A and B, and
100× for C.
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1751In  summary,  we  demonstrated  an  encouraging  and
positive preliminary outcome of early injection of lentivirus-
mediated  siRNA  for  VEGF  in  treatment  of  iris
neovascularization  in  the  monkey  model.  Further  studies
should be performed to investigate the long-term effect of this
strategy.
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